GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Akari Therapeutics AKTX · USD

Health Care · US listing · 🇺🇸 United States

Compare

7.66

+3.93%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Akari Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Akari Therapeutics is based in Tampa, Florida and is incorporated in United Kingdom. Its shares trade on Nasdaq under the ticker AKTX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $17.3m. At that date it held total assets of $47.9m and shareholders' equity of $28.3m.

In its own words

Cancer Society estimates that approximately 626,000 people will die of cancer in the United States in 2026.

Accumulation of thousands of aberrant mis-spliced RNA sequences result in numerous misfolded and unnatural proteins within the cell.

We acquired the rights to PHP-303 and licensed associated know-how from Bayer Pharmaceuticals in March 2017.

This patent family is pending in 12 jurisdictions, and the anticipated expiry of this patent family is April 2043.

T-cells, unique T cells that possess potent anti-tumor activity and can kill cancer cells much faster than conventional T cells.

Quoted from its 10-K, filed 30 Mar 2026. Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
21 Sept 2015
Employees
5
Website
akaritx.com ↗
Head office
401 EAST JACKSON STREET, TAMPA, FL, 33602
Incorporated in
X0
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Akari Therapeutics develops antibody-drug conjugates for cancer-killing toxins in the US market.
  • The lead payload PH1 disrupts spliceosome function to trigger an immune response against cancer.
  • AKTX-101 is a preclinical trop2-targeting ADC designed to treat various solid tumor types.

Weaknesses

  • The company employs only five people, which limits operational capacity and resources significantly.
  • AKTX-101 remains in the preclinical stage, meaning no clinical data is available yet.
  • The firm is headquartered in Tampa, Florida, which may restrict access to major biotech hubs.

Opportunities

  • AKTX-102 is a novel bispecific ADC that utilizes PH1 to treat various solid tumors.
  • The pipeline targets lung, breast, bladder, and gastric cancer types with high unmet needs.
  • PH1 acts as a spliceosome modulator, offering a unique mechanism for disrupting RNA splicing.

Threats

  • Listing on 21 September 2015 means the company has faced long-term market scrutiny.
  • Health Care sector competition is intense, requiring significant capital for successful drug development.
  • Reliance on a single novel payload PH1 creates concentration risk for the entire pipeline.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.